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Abstract 
Promensil is an over the counter plant based hormonal supplement used to treat menopausal 
symptoms, and is considered safer than human estrogen treatments. This project evaluates the model cell 
line, T47D-KBluc, which synthesizes luciferase in response to estrogen receptor binding, which can be 
used to quantify the binding affinity of each hormone. Using both luciferase assays and PCNA, the cell 
was examined for its growth and estrogen receptor activity when exposed to Promensil in order to 
determine that T47D-KBluc is responsive to estrogen like compounds. The findings can be used to 
support future studies of Promensil and its components in order to develop a better understanding of 
phytoestrogen drugs. 
Introduction 
1.1 - Estrogen and Receptors  
Estrogens are a family of steroid based hormones that play key regulative and proliferative roles 
within mammalian organisms. In humans the most common and potent form is 17β-estradiol, but can be 
found in other forms such as estrone and estriol (Katzenellenbogen et al, 2010). These hormones, which 
are primarily produced in the ovaries and adrenal glands, influence changes in proliferation and 
physiology in many areas of the body, most notably in the lumen tissues of the uterus and the tissues of 
the mammary glands. However, they also interact with cells of the liver and pituitary gland (Hewitt & 
Korach, 2002). 
Estrogens facilitate these changes by binding to specific estrogen receptors (ERs), embedded 
within the nuclear membrane of target cells. ERs are members of a larger family known as nuclear 
receptors. These receptors are ligand activated transcription factors that possess highly conserved binding 
domains, enabling them to bind specific ligands and DNA segments. The ligand binding domain (LBD) is 
comprised of 12 transmembrane proteins that play a pivotal role in determining the type of ligand that 
binds to the receptor. In its non - ligand bound form, or Apo LBD, the 12 regions form an anti-parallel α – 
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helical sandwich. Once bound by a specific receptor, the domain undergoes a conformational change. 
Several of the transmembrane proteins will adjust their position to form a stable “pocket” for the ligand. 
In this form, the receptor becomes activated and prepares to bind specific promoter segments.  
Before binding to a specific DNA segment, the newly formed ligand + receptor complex will 
dimerize with other receptors via dimerization loops. These loops consist of zinc finger residues (Cys-476 
and Cys482) that allow the receptors to bind together and form stable homodimers.  These newly formed 
complexes possess DNA binding domains that bind and anchor it on specific response regions of the 
DNA and facilitate gene expression and overall change within the cell. Antagonists are ligands that can 
bind to nuclear receptors and cause conformational change as well. However, these ligands bind to 
receptors and produce complexes that are slightly altered. In some cases this altered conformational 
change disrupts the DNA binding capabilities of receptor and halt gene expression. In the case of ERs, 
tamoxifen acts as an antagonist, especially within cells of the breast. This hormone binds to the ER, 
blocking estrogen hormones from binding and prevents them from stimulating cell proliferation (Tropp, 
2005). Figure 1 shows both domains within an estrogen receptor. 
 
Figure 1: Ligand binding and DNA binding Domains (bio.cmu.edu, 2013) 
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In human cells, estrogen hormones will interact with two of the main isoforms of the ER, α or β. 
These ERs share similar overall functions and estrogen affinity. However, they have distinct differences 
that set them apart. They are distributed uneven throughout the body. ERα have been known to be 
prevalent in growing cells of the uterus while ERβ exists heavily within areas such as the prostate, ovaries 
and salivary glands (Hewitt & Korach, 2002). Figure 2, below depicts other areas in the body where these 
receptors are found. 
 
Figure 2: Areas where Er alpha and beta receptors are found (NR Resoource.org, 2013) 
 
They also have slightly different binding regions, causing them to bind differently toward certain 
ligands.  ERα is 30 times more sensitive to genistein, a phytoestrogen that has estrogenic characteristics, 
compared to its β counterpart. These differences in binding regions also induce results. ERα has been 
known to promote cell proliferation in areas of the breast and uterus when activated by the 17β - estradiol 
ligand. However, ERβ has been shown to have anti-proliferative characteristics in these same areas when 
α receptor is knocked out. Because of these differences, the two receptors are independent of one another. 
To activate these receptors estrogenic ligands enter the cell through its plasma membrane and 
bind to one of the ER isoforms in the nuclear membrane. Once bound by a specific ligand, the ER will 
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dimerize with another receptor to form a homodimer complex. This complex will bind to an estrogen 
responsive element (ERE), a 13 base pair repeat sequence. This binding event stimulates the recruitment 
of other transcription factors and enhancers and stimulates the overall transcription of genes downstream 
(Katzenellebogen et. al, 2000). ERs possess two domains, C and E, that allow them to effectively bind 
hormonal ligands and the EREs found in the DNA (Levin, 2005).  
1.2 - Hormonal Replacement Therapy 
As women age, estrogen levels begins to dissipate as reproductive capabilities fade and they enter 
menopause.  In some women the menopausal stage can be an uncomfortable one, filled with various 
symptoms including hot flashes and atrophy of the uterus. Women, who are breast cancer survivors, may 
experience a more extreme form of these symptoms sooner (depending on when the cancer was 
diagnosed) (Seifert & Kubist, 1999). Female cancer patients often take antagonistic hormones, like 
tamoxifen, to block estrogen receptors and prevent the possibility of cancerous cell proliferation. Though, 
this treatment is effective at halting cancerous growth especially within cells of the mammary glands, it 
still leaves these survivors with reduced estrogen levels (Seifert & Kubist, 1999).  
In the past, women with lower level of estrogen have turned to taking estrogen supplement as a 
therapy for dealing with these adverse effects. Estrogen can provide relief to these symptoms but does 
place these women at risk to redeveloping cancer (Sakamoto et. al, 2010). Previous studies have shown 
that the binding of estradiol (E2) to ER causes an up-regulation and increased sensitivity to cyclin D1, a 
protein that is highly prevalent in cells progressing through the cell cycle. The hormone’s binding can 
also induce anti-apoptotic effects on the cells of the breast. These can lead to unmitigated cell growth and 
an early sign of cancer within women of this age bracket (Sakamoto et. al, 2010). Because of this 
potential threat, alternative hormones have been examined in order to find a replacement. Progesterone, 
coupled with estrogen supplements has produced positive effects by reducing some of the symptoms of 
menopause. But its risk of stimulating dormant cancer cells in cancer survivors eliminated it as a possible 
treatment option. Now over the counter phytoestrogen supplements are currently being used to counter act 
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the reduced estrogen levels and uncomfortable menopausal symptoms that women face as they age 
(Warren, Halpert, 2004). 
1.3 - Phytoestrogens 
Numerous phytoestrogens have been investigated to find a safer alternative for hormone 
replacement therapy. At their core, phytoestrogens consist of a group of plant based hormones possessing 
an affinity for the ER in estrogen targeting cells (Hopert et. al, 2008). Examples of phytoestrogens being 
investigated include isoflavonoids, genistein, daidzein, coumestrol and puerarin (Cherdshewasart, 
Panrainsaen, Picha; 2007).These hormones have attracted attention in recent years for numerous reasons, 
the first being that they are completely natural product; second, it is believed that some of these hormones 
can induce estrogen like activity without supporting unmitigated cellular growth.  Various studies have 
tried to analyze the properties of these hormones. A study conducted in 2007 by Doctors Wichai 
Cherdshewasart Rattana Panriansaen and Porntipa Picha observed the anti-proliferative effects of a plant 
species known as Pueraria Mirifica (P. Mirifica). In regions of Thailand, this plant has been used and 
consumed as an herbal remedy for women entering menopause. During the study, this plant was purified 
via an HPLC revealing several of the phytoestrogens mentions above, suggesting that the plant was 
phytoestrogen rich. To observe the effects of these phytoestrogens, the plants were broken into powdered 
form and dissolved in 0.7mL of distilled water. Concentrations of 10, 100 and 1000 mg/kg were fed daily 
to rats with breast cancer. The results displayed showed rats that received the highest concentrations of 
the plant powder, produced tumors of a lesser size and diameter than those of the control. Tumor cells 
treated with the P.Mirifica, possessed lower levels of the estrogen receptor, perhaps explaining the 
reduction in tumor size (Cherdshewasrt, Panriansaen, Picha, 2007). Though some of the results have been 
promising, uncertainties still remain. What pathway do these phytoestrogens work through? Does it 
simply operate through the estrogen receptor or are other receptors involved? Further research is needed 
to uncover more about these hormones. 
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1.4 - Promensil  
Red clover is the main ingredient in the popular supplement, Promensil, which boasts four main 
phytoestrogen hormones: daidzin, genistin, formononetins, biochanin A (Setchell et al, 2001). Each of 
these components could be eaten in a diet of beans and vegetables, but the direct action these components 
have in concert on human cells is somewhat unknown. Population studies have shown that cancerous 
diseases of the breast and prostate are lower in the Eastern region of the world, where plant based foods 
are an essential and significant part of the diet. It has been hypothesized that certain phytoestrogens, such 
as daidzin and genstein found in soy beans could play a role in this (Lof, Weiderpass, 2006 ). 
 
1.5 - T47D KBluc 
T47D-KBluc has been used in the past to analyze the estrogenic and antiestrogenic properties of 
certain hormones. The cell line was created using T47D, an adherent breast cancer cell line, commonly 
used in cancer research. T47D was transfected with triplet estrogen responsive elements (ERE) and a 
luciferase reporter gene. These components allow the cell to transcribe luciferase in response to certain 
compounds, human and foreign, acting through the estrogen receptor. As ligand forms a union with 
multiple estrogen receptors (ER), these receptors will dimerize and bind to corresponding coactivators in 
the area. These components will then interact with the EREs of the luciferase reporter construct and 
activate the translation of the luciferase gene further downstream. Luciferin can be added to the cells, 
causing a reaction with luciferase and producing light relative to the estrogenic activity of the chemical 
under scrutiny. Quantifying this light can characterize the estrogenic activity of a compound (Wilson et 
al, 2004).  
1.6 – Our aim 
In this study, the aim was to determine whether or not the T47D kBluc cell line could act as a 
model candidate for further investigation of the phytoestrogen mode of action. Luciferase assays were 
conducted on the cell line to determine the luciferase reporter sensitivity toward phytoestrogen, in 
9 
 
comparison to estrogen. Prior to conducting these assays, we expected the estradiol to cause an increase in 
luminescence from the cell line. The estradiol would increase its interactions with estrogen receptors, 
resulting in the overall increase in translation of the luciferase enzyme. We believed that cells exposed to 
Promensil supplements would display a decreased luminescence in comparison to estradiol. In these cells, 
interactions with estrogen receptors are reduced resulting in lower amounts of luciferase and 
luminescence capabilities. Our control, which was cells exposed to ethanol, was predicted to a produce 
baseline amount of luminescence. 
Immunoblots, assaying for the presence of PCNA, were also conducted. PCNA or Proliferative 
Cell Nuclear Antigen is a known factor in the cell cycle and the proliferation of cells. This protein plays a 
key role in DNA replication by interacting with the DNA polymerase of the leading strand and increasing 
its transcriptional efficiency (http://www.uniprot.org/uniprot/P12004). Before conducting the blot, we 
anticipated that the PCNA signal would be weaker in cells exposed to the Promensil supplements due to 
the presence of anti-proliferative phytoestrogens (Le Bail et al, 1999). We also believed that cell samples 
exposed to estrogen would sharply increase the PCNA signal when compared to the control because of its 
known proliferative properties (Wilson et al, 2004).  
Methodology 
2.1 Cell Culture 
T47D-KBluc cells were cultured in DMEM + 10% FBS + 1% Pen/strep on both T25 and T75 
flasks, incubated at 37° C %5 CO2. Cells were grown for ~96 hours or until high confluence was reached. 
Flasks were then trypsinized and cultured in either DMEM + 10% FBS (Dextran charcoal stripped) + 
1%pen/strep without phenol red or the original media mentioned above. Before use in experimental 
procedures, cells grew in phenol red free medium for ~96 hours before being plated on either 12 well 
plates at 100,000 cells per well, or 96 well plates at 10,000 cells per well.  
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2.2 Hormone Dosing 
Soluble Promensil and estradiol concentrations were created using serial dilution techniques. A 
stock of estradiol at 10-7 molar was created using powdered estradiol and ethanol.  Tenfold serial dilutions 
made a range of 10-8 to 10-13 molar estradiol. To create a soluble Promensil solution, three tablets of 
Promensil were crushed and refluxed in 100 ml of methanol for 1 hour at ~65° C. Tenfold serial dilutions 
using ethanol were performed on the refluxed pills to create a range from 10-1 to 10-4 dilutions of the 
original. This range of dilutions was created to capture the doses at which human cells would be exposed 
to in a single day of taking the supplement in accordance to the consumer suggested dosing. The exact 
concentration of hormones in the Promensil extract was unknown but was considered less than 10-7 molar 
because the extract remained homogenous when refrigerated, whereas 10-7 molar estradiol formed 
crystals.  
2.3 PCNA 
Cells were grown on 12 well plates at 100,000 cells per well in ~1ml of medium for 24 hours 
before exposure to hormones. 50ul of ethanol, estradiol solutions 10-8 to 10-13 and Promensil 10-1 to 10-4 
solutions were added to the wells and incubated for ~24 hours. Media and sample solution was aspirated 
away to dry the cells before placing the plates in the -80° C freezer to lyse the cells. The contents of the 
wells were collected by scraping the wells in 200ul of PBS. The protein content of the wells was 
determined using a Bradford assay. The absorbance was read at 580nm to determine the protein 
concentration of the samples. Using the results of the Bradford assay the samples were diluted in PBS to 
normalize the concentration of each sample equal to the lowest concentration of protein. Samples were 
denatured by boiling for 5 minutes in loading buffer containing SDS, beta mercaptoethanol before being 
run on a Bio-Rad Mini-Protean TGX 4–20% precast polyacrylamide gel . Following elctrophoretic 
separation, the proteins were transferred onto a polvinylpyrrolidine membrane using a semi dry blotter to 
be treated for PCNA detection. The membrane was first exposed to blocking buffer, ~5% non-fat dry 
milk, for 30 minutes. After rinsing in TBS, 10nM Tris-Cl+150nMNaCl pH7.4, the membrane was 
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exposed to 0.02% mouse monoclonal Anti-PCNA antibody in TBS+0.1% Tween for enough time to bind 
to the PCNA bands, ~1 hour at room temperature. The membrane was then exposed to a secondary 
antibody, Santa Cruz Biotech alkaline phosphatase conjugated gGoat anti-mouse IgG. After rinsing in 
TBS and TBS with 0.1% Tween-20, the membrane was finally exposed to Sigma Fast BCIP/NBT to 
visualize the bands.  
2.4 Luciferase assay 
Cells were grown on 96 well plated at 1,000, 10,000, and 20,000 cells per well in 100ul of phenol 
red free medium for ~24 hours. 2ul of ethanol, estradiol solution or Promensil solution were added to 
each well, and the cells were incubated for ~24 hours. 100ul of Promega Steady-Glow® luciferin solution 
was added to each well to lyse the cells and begin the luciferase reaction. The wells were covered with tin 
foil to reduce exposure to external light and the reaction was given ~15 minutes to take place. A Perkins 
Elmer LS55 fluorescence spectrophotometer with a 96 well plate reader was used to measure the well 
luminescence.  Both specific wavelength scans at 560 nm and full spectrum scans of the wells were 
performed to measure the light output of the luciferase assays, where in every case, the excitation lamp 
was manually turned off to prevent external excitation of the assay. 
Results 
3.1 PCNA Blot 
Ten samples from the T47D-KBluc cell line were assayed for PCNA production after 24 hours of 
exposure to varying concentrations of estradiol and the promensil supplement. After conducting a 
preliminary blot to determine that 100,000 cells produced the optimal PCNA signal, in figure 3, ten 
samples were placed in electrophoresis wells and assayed for PCNA by immunoblotting as detailed in 
methods. 
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Figure 3. Preliminary PCNA Blot containing with 50,000, 100,000 and 200,000 cell samples 
 
Figure 4. Experimental PCNA Blot containing cell samples dosed with Estradiol and Promensil at concentrations 
indicated above each band. 
Lanes 1, 3, 4 and 5 contain varying concentrations of estradiol. Lanes 6 through 10 contained varying 
concentrations of promensil. Stars found under lanes 4 and 5 indicate loading errors and should be 
disregarded.  
As seen in Figure 4, there was no discernible visual difference in the signal strength between the 
control and cells at any level of estrogen treatment. Cells exposed to this hormone produced an almost 
identical signal to cells exposed to just ethanol, our control. However, lanes containing cells treated with 
Promensil supplements (lanes 6-10) produced a reduced PCNA signal, supporting the notion that a 
decrease in cellular proliferation occurred. However there is no visual correlation between the signal 
strength and the dose of Promensil added. 
3.2 Luciferase Assay 
Luciferase assays were intended to quantify luminescence emitted from T47D cells following 
dosing with estradiol and Promensil. Two sets of 12 samples containing 10,000 and 20,000 cells were 
plated onto a 96 well plate. One set of cells was exposed with ethanol to act as a control while the 
remaining samples were exposed to the test hormones. Luminescence from this plate was analyzed with a 
Fluorescence Spectrophotometer and interpreted with the FL Winlab software. The data from the assay 
proved to be inconclusive. The control samples produced almost identical luminescence values when 
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compared to the test samples. When the data was displayed on graphs, the observed luminescence 
covered almost the entire white light spectrum, as opposed to one particular peak close to the predicted 
560nm. The assay was additionally performed multiple times with 1,000 and 100,000 cells were per well 
to determine if the cell concentration could affect the assay. When the cell concentrations were changed, 
similar results were received from the assay. 
Discussion 
The PCNA blot performed on cells exposed to both estradiol and Promensil indicated a reduced 
signaling in lanes containing Promensil, inferring that the Promensil reduced the rate of growth in T47D-
kBluc. This data is consistent with what is predicted, though the dosage concentration did not appear to 
have a noticeable effect on the growth rate, where the signal in lanes with cells exposed to Promensil 10-1 
and 10-3 dilutions appear equivalent. No significant response between dosages could mean that the cells 
were saturated by the doses, indicating that the lowest dilution induced the same interaction with the cells 
as the highest. This data implies that a larger dilution pool of the Promensil extract should be examined. 
In each case, the Promensil reduced PCNA levels, indicating that T47D-kBluc responded to Promensil by 
reducing growth.  The estradiol lanes10-8 and 10-9 signaled at roughly equivalent intensity as the control, 
which was not predicted. In previous examinations of the cell line by Wilson, Bobseine, Grey in a 
preliminary characterization of the cell line, estradiol was observed to increase growth, implying that the 
PCNA blot was performed using protein concentrations that exceeded the sensitive range of the blot 
(Wilson, 2004). The 10-12 lane of estradiol showed reduced signaling, similar to the Promensil lanes, 
indicating that the lower concentration of estradiol grew slower than the control, which is does not 
correspond with the predicted effects of estradiol. This result implies that the 10-12 lane was run using a 
sample with less original protein concentration, or that the control was run using elevated protein levels, 
which could explain why the cells exposed to 10-8 and 10-9 lanes had signaling equal to the control. The 
PCNA blot to measure cell growth in estradiol and Promensil deserves further examination using lower 
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base protein concentrations in order to further understand if T47D-KBluc is responsive to both estradiol 
and Promensil. 
 Over the multiple examinations of T47D-KBluc, no conclusion could be drawn on the cell lines 
ability to luminesce when exposed to luciferin. Using multiple settings and measuring techniques, T47D-
KBluc no specific luminescence was detected.  The nonspecific emission spectrum suggested that either 
the assay itself was not working or that the instrumentation settings were not optimized for detection.  A 
florescence spectrophotometer, which is designed to record light emitted from samples in an excited state, 
was used to record the luminescence of the experiments. This machine should have been able to record 
emitted light in the absence of excitation, but it is not the ideal machine for the application. The 
sensitivity of the florescence spectrophotometer could not be identified due to the lack of a positive 
control, a solution that was known to emit light at a similar wavelength to the luciferase reaction. A 
luminometer is designed to record light without using a light source to excite the sample and measure 
only the light produced by a reaction. Without checking the luciferase reaction in both machines with a 
positive control, it cannot be determined if T47D-KBluc produces luciferase when the estrogen receptor is 
activated.  
 The lack of results from the luciferase assay could indicate that the particular cells being used 
may have mutated since the original T47D-kBluc cell line was received and cultured. Because the 
cultures underwent numerous splitting stages and growth on multiple types of media, cells could have 
been accidently selected for a strain of T47 that no longer had a functioning luciferase reporter or an 
unknown error in the pathway that no longer allows for luciferase be transcribed.  
 Ultimately, our assays were unable to distinctly endorse the T47D-KBluc as a model candidate 
for further investigation of phytoestrogens. However, the cell line requires further examination using both 
of the previously used techniques, PCNA and luciferase assays. The PCNA blot did indicate that the cell 
line reacted as expected to the Promensil and estradiol. This blot should be repeated using a reduced 
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protein density, in order to get a more appropriate positive control from cells dosed with estradiol. A 
positive control from cells exposed to estradiol would strength the results seen in the study.  
For the luciferase assay, a preliminary step can be made. To determine if the cell line we possess 
can still accurately report using the assay, rtPCR, a gene sequencing technique, can be used to determine 
if the cells still contain the correct genes required for the transcription of luciferase. This examination 
would only be necessary if the use of a luminometer with a positive control have been ruled out as viable 
examination techniques.  
This examination of T47D-KBluc determined that the cell line has potential for being a model 
cell line to examine Promensil and other phytoestrogen drugs. If the luciferase assay is determined to 
respond to estradiol and Promensil in a measureable way, the cell line can be used to test individual 
components that make up the drug. Promesil is not made up of pure known substances, but a cocktail of 
components that are contained in red clover. High performance liquid chromatography, or HPLC, has 
revealed a multitude of different phytoestrogens including but not limited to Daidzein and Formononetin 
(Setchell, 2001). The extract used in the study has an effect on the cell line, but it is unclear as to which 
components of Promensil can induce changes. To further examine Promesil with a functioning luciferase 
assay, the individual phytoestrogens identified could be purified and applied to the cells to determine 
which chemicals are acting on the estrogen receptor. PCNA could also be used to understand which 
purified phytoestrogens reduce growth and if any increase growth, which could prove that Promensil is 
not an ideal drug composition and deserves purification. With each component of Promensil being 
analyzed for its effect on growth and for its action in the estrogen pathway, a drug with more accurately 
calculated ingredients to counteract menopausal symptoms while having anti-carcinogenic affect could be 
developed.  
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